Corever in the Treatment of Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 134 participants.
Also called NCT02432937
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 134 participants
- Sponsor
- TSH Biopharm Corporation Limited
- Registry
-
NCT02432937
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT02432937. Randomized; double masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Corever in the Treatment of Hypertension
- Condition
- Hypertension
- Intervention (Drug)
- Corever
- Lead sponsor
- TSH Biopharm Corporation Limited
Record details
- Record id
cardio:ct-nct02432937- Content hash
6adf318301e0dc3bd0de07d13dd72ea90febeab98f8b90d0373d611f97f459a8